Zobrazeno 1 - 10 of 18 pro vyhledávání: '"G. M. Eisen"'
1
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac
Autor: Thomas A. Burke, Jay L. Goldstein, James B. Lefkowith, G. M. Eisen, G. S. Geis, B. M. Peña
Publikováno v: Alimentary Pharmacology & Therapeutics. 16:819-827
Aim: To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability. Methods: In one of the two protocols comprising the Celecoxib Long-Term Arthritis Safety Study, a randomized double-blind trial, pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::710dc267c4d91321ef63439c013a9887
https://doi.org/10.1046/j.1365-2036.2002.01219.x
Zobrazit plný text záznamu
2
MiraLAX vs. Golytely: is there a significant difference in the adenoma detection rate?
Autor: B K, Enestvedt, M, Brian Fennerty, A, Zaman, G M, Eisen
Publikováno v: Alimentary pharmacologytherapeutics. 34(7)
In recent clinical trials (RCT) of bowel preparation, Golytely was more efficacious than MiraLAX. We hypothesised that there is a difference in adenoma detection between Golytely and MiraLAX.To compare the adenoma detection rate (ADR) between these b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9fbbd36ad69099c088e900989ff3d4df
https://pubmed.ncbi.nlm.nih.gov/21848798
Zobrazit plný text záznamu
4
Randomised clinical trial: MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability in bowel preparation for colonoscopy
Autor: B K, Enestvedt, M B, Fennerty, G M, Eisen
Publikováno v: Alimentary pharmacologytherapeutics. 33(1)
MiraLAX is gaining acceptance as a bowel cleanser for colonoscopy. We hypothesize that MiraLAX/Gatorade is as efficacious for bowel cleansing as Golytely and is more tolerable for patients undergoing screening colonoscopy.To compare bowel preparation
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::433d7dcdb31b5c525c90888dcbed3127
https://pubmed.ncbi.nlm.nih.gov/21083586
Zobrazit plný text záznamu
5
Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy
Autor: J L, Goldstein, G M, Eisen, B, Lewis, I M, Gralnek, J, Aisenberg, P, Bhadra, M F, Berger
Publikováno v: Alimentary pharmacologytherapeutics. 25(10)
Small bowel mucosal injury associated with non-selective non-steroidal anti-inflammatory drugs is being increasingly recognized.To evaluate the incidence of small bowel injury in healthy subjects receiving celecoxib or ibuprofen plus omeprazole using
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4b644770a991e19f79af8f9cb6b796f2
https://pubmed.ncbi.nlm.nih.gov/17451567
Zobrazit plný text záznamu
6
A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule
Autor: R, Eliakim, K, Yassin, I, Shlomi, A, Suissa, G M, Eisen
Publikováno v: Alimentary pharmacologytherapeutics. 20(10)
Gastro-oesophageal reflux disease is a common entity. Erosive oesophagitis, ulcers and Barrett's oesophagus, which is found in up to 10% of gastro-oesophageal reflux disease patients, characterize severe gastro-oesophageal reflux disease. Patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::91346d188e045398f72c5735233b3b0a
https://pubmed.ncbi.nlm.nih.gov/15569110
Zobrazit plný text záznamu
7
Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib
Autor: J L, Goldstein, G M, Eisen, N, Agrawal, W F, Stenson, J D, Kent, K M, Verburg
Publikováno v: Alimentary pharmacologytherapeutics. 20(5)
In a predefined analysis, data were pooled from eight blinded, randomized, controlled trials, and separately from three long-term, open-label trials to determine the rate of upper gastrointestinal ulcer complications with the cyclo-oxygenase-2 select
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9b370cd3757241acd07eb23ac52882fc
https://pubmed.ncbi.nlm.nih.gov/15339324
Zobrazit plný text záznamu
8
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac
Autor: J L, Goldstein, G M, Eisen, T A, Burke, B M, Peña, J, Lefkowith, G S, Geis
Publikováno v: Alimentary pharmacologytherapeutics. 16(4)
To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability.In one of the two protocols comprising the Celecoxib Long-Term Arthritis Safety Study, a randomized double-blind trial, patients complete
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3499c6dd284202f5c89bf74a1c29dfe7
https://pubmed.ncbi.nlm.nih.gov/11929402
Zobrazit plný text záznamu
10
Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus. A study of 700 biopsy specimens
Autor: P, Bhargava, G M, Eisen, D A, Holterman, N, Azumi, D P, Hartmann, J J, Hanfelt, S B, Benjamin, M E, Lippman, E A, Montgomery
Publikováno v: American journal of clinical pathology. 114(4)
Surveillance methods in Barrett esophagus (BE) using light microscopic examination of random biopsy specimens may miss focal dysplasia. In addition, dysplastic foci identified initially may not be relocated subsequently, making chemoprevention studie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1f90c08da311035dfd582bf8b68c1628
https://pubmed.ncbi.nlm.nih.gov/11026101
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje